A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease

Channing Laboratory, Boston, MA 02115, USA.
American Journal of Clinical Nutrition (Impact Factor: 6.92). 01/2009; 88(6):1602-10. DOI: 10.3945/ajcn.2008.26404
Source: PubMed

ABSTRACT High homocysteine concentrations may be neurotoxic and contribute to cognitive decline in older persons.
The objective was to examine the effect of supplementation with folic acid, vitamin B-12, and vitamin B-6 on cognitive change in women with cardiovascular disease (CVD) or CVD risk factors.
The Women's Antioxidant and Folic Acid Cardiovascular Study is a randomized placebo-controlled trial designed to test the effect of a combination of B vitamins (2.5 mg folic acid/d, 50 mg vitamin B-6/d, and 1 mg vitamin B-12/d) on secondary prevention of CVD. Female health professionals aged >or=40 y (n = 5442) with CVD or >or=3 coronary risk factors in 1998 (after folic acid fortification began in the United States) were randomly assigned to treatment. Shortly after randomization (mean: 1.2 y), a substudy of cognitive function was initiated among 2009 participants aged >or=65 y. Telephone cognitive function testing was administered up to 4 times over 5.4 y with 5 tests of general cognition, verbal memory, and category fluency. Repeated-measures analyses were conducted, and the primary outcome was a global composite score averaging all test results.
Mean cognitive change from baseline did not differ between the B vitamin and placebo groups (difference in change in global score: 0.03; 95% CI: -0.03, 0.08; P = 0.30). However, supplementation appeared to preserve cognition among women with a low baseline dietary intake of B vitamins.
Combined B vitamin supplementation did not delay cognitive decline among women with CVD or CVD risk factors. The possible cognitive benefits of supplementation among women with a low dietary intake of B vitamins warrant further study.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin supplements are used by large numbers of older adults. Although vitamins serve several functions in the body, the benefits or harm of routine supplementation are far from clear. Data from studies over the last decade are reviewed to enable an understanding. Summarized data from studies conducted over the last few years, pertinent to the use of vitamins, as multivitamin combinations and as individual vitamins specifically A, D, E, C, and the B group, are presented. This review targets the benefits and harm of multivitamins when used to lower the risk of cancer, cardiovascular and cerebrovascular disease, visual disorders (e.g., cataracts and age-related macular degeneration), and bone disease. The effects of vitamins on total mortality are discussed. In addition, isolated or multiple vitamin deficiencies, their predisposing settings and manifestations from mild-to-life-threatening illness are discussed. Data from studies demonstrate considerable variations, most confirming little to no benefit following supplementation in healthy adults. However, clear roles exist for vitamin supplementation in states of deficiency and in subgroups of older adults at high risk for deficiency of specific or multiple vitamins. In these settings, vitamin supplements help prevent or correct deficiency and related manifestations.
  • American Journal of Clinical Nutrition 02/2015; 101(2):414-415. DOI:10.3945/ajcn.114.097808 · 6.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Elevated plasma homocysteine (hcy) levels, also known as hyperhomocysteinemia (hhcy), have been associated with cognitive impairment and neurodegenerative disorders. Hhcy has been attributed to deficiency of B vitamins which can adversely affect the brain and result in memory loss and poor attention power. Monitoring hcy levels and the use of vitamin supplementation to treat hhcy may therefore prove advantageous for the prevention and management of cognitive impairment. With this in consideration, we measured plasma hcy, folate and vitamin B12 levels in 639 subjects from different age groups in two sub-regions of India. Cognitive function was also measured using attention span and immediate and delayed memory recall tests. Depression scores were obtained using the Beck Depression Inventory-II and functional impairment was assessed using the functional activities questionnaire (FAQ) score. As hhcy has also been linked to inflammation, plasma levels of high sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) were also measured. The results demonstrated significant negative correlations between hcy levels and folic acid levels, vitamin B12 levels and cognitive performance (attention span and delayed but not immediate memory recall) along with significant positive correlations between hcy levels and depression scores and hsCRP (but not IL-6) levels. A positive correlation was also observed between hcy levels and FAQ scores, however this was not found to be significant. Based on these results, folic acid and vitamin B12 intervention in people with elevated hcy levels in India could prove to be effective in lowering hcy levels and help maintain or improve cognitive function. Copyright © 2015. Published by Elsevier B.V.
    Behavioural Brain Research 01/2015; 283. DOI:10.1016/j.bbr.2015.01.016 · 3.39 Impact Factor

Full-text (2 Sources)

Available from
Nov 26, 2014